Title
Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population
Date Issued
01 January 2009
Access level
open access
Resource Type
journal article
Author(s)
Guo L.
Deshmukh H.
Lu R.
Vidal G.S.
Kelly J.A.
Kaufman K.M.
Dominguez N.
Klein W.
Kim-Howard X.
Bruner G.R.
Scofield R.H.
Moser K.L.
Gaffney P.M.
Dozmorov I.M.
Gilkeson G.S.
Wakeland E.K.
Li Q.Z.
Langefeld C.D.
Marion M.C.
Williams A.H.
Divers J.
Brown E.E.
Kimberly R.P.
Edberg J.C.
Ramsey-Goldman R.
Reveille J.D.
McGwin G.
Vilá L.M.
Petri M.A.
Vyse T.J.
Merrill J.T.
James J.A.
Nath S.K.
Harley J.B.
Guthridge J.M.
University of Alabama at Birmingham
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease with highly variable clinical presentation. Patients suffer from immunological abnormalities that target T-cell, B-cell and accessory cell functions. B cells are hyperactive in SLE patients. An adapter protein expressed in B cells called BANK1 (B-cell scaffold protein with ankyrin repeats) was reported in a previous study to be associated with SLE in a European population. The objective of this study was to assess the BANK1 genotype-phenotype association in an independent replication sample. We genotyped 38 single nucleotide polymorphisms (SNPs) in BANK1 on 1892 European-derived SLE patients and 2652 European-derived controls. The strongest associations with SLE and BANK1 were at rs17266594 (corrected P-value = 1.97 × 10-5, odds ratio (OR) = 1.22, 95% CI 1.12-1.34) and rs10516487 (corrected P-value = 2.59 × 10-5, OR = 1.22, 95% CI 1.11-1.34). Our findings suggest that the association is explained by these two SNPs, confirming previous reports that these polymorphisms contribute to the risk of developing lupus. Analysis of patient subsets enriched for hematological, immunological and renal ACR criteria or the levels of autoantibodies, such as anti-RNP A and anti-SmRNP, uncovers additional BANK1 associations. Our results suggest that BANK1 polymorphisms alter immune system development and function to increase the risk for developing lupus.
Start page
531
End page
538
Volume
10
Issue
5
Language
English
OCDE Knowledge area
Inmunología
Reumatología
Scopus EID
2-s2.0-67849097327
PubMed ID
Source
Genes and Immunity
ISSN of the container
14664879
Sponsor(s)
Support: This project was funded by National Institutes of Health RR020143 (JMG and JBH), RR015577 (JMG, JBH, JAJ), HHSN266200500026C (JMG and JAJ), AR053483 (JMG, SKN and JAJ), AI063274 (PMG), AI031584 (JBH, JMG, JAJ), AR052125 (PMG), AR043247 (KLM), Kirkland Scholar awards (JBH and JAJ), AR049084 (SKN, JBH, RPK), AR42460 (JBH), AR12253 (JBH), AR62277 (JBH), AI24717 (JBH), AR48940 (JBH, JAJ), Alliance for Lupus Research (JBH), the US Department of Veterans Affairs (JBH) and OHRS award for project number HR08-037 from the Oklahoma Center for the Advancement of Science and Technology (JMG). Dr Harley has received consulting fees, speaking fees and/ or director’s fees from Bio-Rad Laboratories; Merck; UCB Inc.; ImmunoVision Inc.; IVAX Diagnostics and JK Autoimmunity and owns stock or stock options in IVAX Diagnostics.
Sources of information:
Directorio de Producción Científica
Scopus